Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of AV608 on Central Processing of Visceral Stimuli in Subjects With Irritable Bowel Syndrome
Sponsor: Avera Pharmaceuticals
Terminated
Animal Safety Data
Other terminated trials from Avera Pharmaceuticals
More terminations from Avera Pharmaceuticals
Listed as NCT00316550, this PHASE1 trial focuses on Irritable Bowel Syndrome (IBS) and remains terminated or withdrawn. Sponsored by Avera Pharmaceuticals, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avera Pharmaceuticals
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .